Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 807

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Kimball, Alexa B., Okun, Martin M., Williams, David A., Gottlieb, Alice B., Papp, Kim A., Zouboulis, Christos C., Armstrong, April W., Kerdel, Francisco, Gold, Michael H., Forman, Seth B., Korman, Neil J., Giamarellos-Bourboulis, Evangelos J., Crowley, Jeffrey J., Lynde, Charles, Reguiai, Ziad, Prens, Errol-Prospero, Alwawi, Eihab, Mostafa, Nael M., Pinsky, Brett, Sundaram, Murali, Gu, Yihua, Carlson, Dawn M., Jemec, Gregor B.E.·2016·New England Journal of Medicine

Abstract

BACKGROUND: Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa. METHODS: PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods. In period 1, patients were randomly assigned in a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks. In period 2, patients were reassigned to adalimumab at a weekly or every-other-week dose or to placebo for 24 weeks. The primary end point was a clinical response, defined as at least a 50% reduction from baseline in the abscess and inflammatory-nodule count, with no increase in abscess or draining-fistula counts, at week 12. RESULTS: We enrolled 307 patients in PIONEER I and 326 in PIONEER II. Clinical response rates at week 12 were significantly higher for the groups receiving adalimumab weekly than for the placebo groups: 41.8% versus 26.0% in PIONEER I (P=0.003) and 58.9% versus 27.6% in PIONEER II (P<0.001). Patients receiving adalimumab had significantly greater improvement than the placebo groups in rank-ordered secondary outcomes (lesions, pain, and the modified Sartorius score for disease severity) at week 12 in PIONEER II only. Serious adverse events in period 1 (excluding worsening of underlying disease) occurred in 1.3% of patients receiving adalimumab and 1.3% of those receiving placebo in PIONEER I and in 1.8% and 3.7% of patients, respectively, in PIONEER II. In period 2, the rates of serious adverse events were 4.6% or less in all the groups in both studies, with no significant between-group differences. CONCLUSIONS: Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar in the study groups. (Funded by AbbVie; ClinicalTrials.gov numbers, NCT01468207 and NCT01468233 for PIONEER I and PIONEER II, respectively.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1504370

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 807

Metadata

Authors
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., Korman, N. J., Giamarellos-Bourboulis, E. J., Crowley, J. J., Lynde, C., Reguiai, Z., Prens, E.-P., Alwawi, E., Mostafa, N. M., Pinsky, B., Sundaram, M., Gu, Y., Carlson, D. M., & Jemec, G. B. E.
Venue
New England Journal of Medicine
Published
2016-08-04
Volume
375
Issue
5
Pages
422-434
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2503109448
Cited by
807
References
1
FWCI
60.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. https://app.cochat.ai/papers/10.1056/nejmoa1504370
The paper
Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., Korman, N. J., Giamarellos-Bourboulis, E. J., Crowley, J. J., Lynde, C., Reguiai, Z., Prens, E.-P., Alwawi, E., Mostafa, N. M., Pinsky, B., . . . Jemec, G. B. E. (2016). Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1504370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.